Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
Introduction Increasingly in pharmacoepidemiology, linking is required to enrich analytic data to more accurately define study populations, enable adjustment for confounding, and improve capture of health outcomes. When creating such novel linked datasets, researchers should consider their suitabil...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Swansea University
2020-12-01
|
Series: | International Journal of Population Data Science |
Online Access: | https://ijpds.org/article/view/1572 |
id |
doaj-bf3b26a56c9548bd89c934a4b901f0ba |
---|---|
record_format |
Article |
spelling |
doaj-bf3b26a56c9548bd89c934a4b901f0ba2021-02-10T16:42:15ZengSwansea UniversityInternational Journal of Population Data Science2399-49082020-12-015510.23889/ijpds.v5i5.1572Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent ReportingNicole Pratt0Danielle Chun1Kourtney Davis2Brad Hammill3Christian Hampp4Christina Mack5Anne-Marie Meyer6Sudha Raman7Donna Rivera8Soko Setoguchi9Til Stürmer10Jennifer Lund11University of South Australia, on behalf of the International Society of Pharmacoepidemiology Working Group on the feasibility, evaluation and reporting of data-linkage studies in pharmacoepidemiologyUniversity of North CarolinaGlobal Epidemiology, Janssen R&D, Titusville, NJ and University of North CarolinaDuke UniversityU.S. Food and Drug AdministrationReal-World and Analytic Solutions, IQVIA,Research Triangle Park, Durham, NC, USA and University of North CarolinaReal World Data Collaborations, Personalized Health Care (PHC), F. Hoffmann-La RocheDuke University, North CarolinaNational Cancer Institute Rutgers UniversityUniversity of North CarolinaUniversity of North Carolina Introduction Increasingly in pharmacoepidemiology, linking is required to enrich analytic data to more accurately define study populations, enable adjustment for confounding, and improve capture of health outcomes. When creating such novel linked datasets, researchers should consider their suitability to meet research objectives, assess source data completeness and population coverage, and ensure well-defined data governance standards and protections exist. Additionally, while the RECORD-PE guidelines assist in the reporting of studies using observational health data specific to pharmacoepidemiology, they do not address the unique requirements for transparent evaluation and reporting of the data linkage process. Objectives and Approach We aimed to 1) provide guidance on data linkage appropriateness and feasibility to plan purposeful and sustainable new linkages that advance pharmacoepidemiological research and 2) generate a checklist with specific recommendations to assist researchers in providing clear and transparent assessment of the linkage process. To develop these guidelines, a working group comprised of members of the International Society of harmacoepidemiology was formed. Recommendations were open for comment by Society members and endorsed by the Society. Results Guidance for feasibility assessment was categorized into five domains: (1) research objectives and justification; (2) data quality and completeness; (3) the linkage process; (4) data ownership and governance; and (5) overall value added by linkage. A checklist for evaluation and reporting of data-linkage processes covered five domains including; (1) data sources; (2) linkage variables; (3) linkage methods; (4) linkage results; and (5) linkage evaluation, including validation and verification of the resulting linked data. Conclusion/Implications Our guidelines for data linkage feasibility assessment and reporting can be used to inform the design of sustainable linked data resources and for transparent communication of linkage processes. Together, these guidelines will help various stakeholders to critically assess the potential for bias in research based on linked data and help generate actionable evidence. https://ijpds.org/article/view/1572 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nicole Pratt Danielle Chun Kourtney Davis Brad Hammill Christian Hampp Christina Mack Anne-Marie Meyer Sudha Raman Donna Rivera Soko Setoguchi Til Stürmer Jennifer Lund |
spellingShingle |
Nicole Pratt Danielle Chun Kourtney Davis Brad Hammill Christian Hampp Christina Mack Anne-Marie Meyer Sudha Raman Donna Rivera Soko Setoguchi Til Stürmer Jennifer Lund Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting International Journal of Population Data Science |
author_facet |
Nicole Pratt Danielle Chun Kourtney Davis Brad Hammill Christian Hampp Christina Mack Anne-Marie Meyer Sudha Raman Donna Rivera Soko Setoguchi Til Stürmer Jennifer Lund |
author_sort |
Nicole Pratt |
title |
Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting |
title_short |
Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting |
title_full |
Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting |
title_fullStr |
Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting |
title_full_unstemmed |
Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting |
title_sort |
guidelines for data linkage in pharmacoepidemiology: assessing feasibility, evaluating quality and transparent reporting |
publisher |
Swansea University |
series |
International Journal of Population Data Science |
issn |
2399-4908 |
publishDate |
2020-12-01 |
description |
Introduction
Increasingly in pharmacoepidemiology, linking is required to enrich analytic data to more accurately define study populations, enable adjustment for confounding, and improve capture of health outcomes. When creating such novel linked datasets, researchers should consider their suitability to meet research objectives, assess source data completeness and population coverage, and ensure well-defined data governance standards and protections exist. Additionally, while the RECORD-PE guidelines assist in the reporting of studies using observational health data specific to pharmacoepidemiology, they do not address the unique requirements for transparent evaluation and reporting of the data linkage process.
Objectives and Approach
We aimed to 1) provide guidance on data linkage appropriateness and feasibility to plan purposeful and sustainable new linkages that advance pharmacoepidemiological research and 2) generate a checklist with specific recommendations to assist researchers in providing clear and transparent assessment of the linkage process. To develop these guidelines, a working group comprised of members of the International Society of harmacoepidemiology was formed. Recommendations were open for comment by Society members and endorsed by the Society.
Results
Guidance for feasibility assessment was categorized into five domains: (1) research objectives and justification; (2) data quality and completeness; (3) the linkage process; (4) data ownership and governance; and (5) overall value added by linkage. A checklist for evaluation and reporting of data-linkage processes covered five domains including; (1) data sources; (2) linkage variables; (3) linkage methods; (4) linkage results; and (5) linkage evaluation, including validation and verification of the resulting linked data.
Conclusion/Implications
Our guidelines for data linkage feasibility assessment and reporting can be used to inform the design of sustainable linked data resources and for transparent communication of linkage processes. Together, these guidelines will help various stakeholders to critically assess the potential for bias in research based on linked data and help generate actionable evidence.
|
url |
https://ijpds.org/article/view/1572 |
work_keys_str_mv |
AT nicolepratt guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT daniellechun guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT kourtneydavis guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT bradhammill guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT christianhampp guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT christinamack guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT annemariemeyer guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT sudharaman guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT donnarivera guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT sokosetoguchi guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT tilsturmer guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting AT jenniferlund guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting |
_version_ |
1724275202766929920 |